Dr. Grunwald on the Efficacy of 19-28z CAR T-Cell Therapy in B-ALL

Video

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Michael R. Grunwald, MD, FACP, clinical assistant professor of medicine, University of North Carolina, hematologist/oncologist, Levine Cancer Institute, Atrium Health, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL).

Long-term follow-up results of a phase 1 trial (NCT01044069) demonstrated a median overall survival of 12.9 months with 19-28z CAR T-cell therapy in adult patients with relapsed/refractory B-ALL, says Grunwald.

Overall, 53 patients with heavily pretreated disease received the 19-28z CAR T-cell therapy. Nineteen of these patients (36%) had undergone prior allogeneic hematopoietic stem cell transplant and 13 (25%) received prior blinatumomab (Blincyto), Grunwald explains. Patients were a median of 44 years old (range, 23-74), adds Grunwald.

Regarding efficacy, 83% of patients achieved a complete remission with 19-28z CAR T-cell therapy, says Grunwald. Some modifications were made during the study treatment with the goal of reducing CAR T-cell therapy–related toxicities, such as cytokine release syndrome, Grunwald says. Fractionating the doses of cells may reduce the rate of toxicity in adults; however, the promising efficacy signal suggests that this therapy should be evaluated further in patients with relapsed/refractory B-ALL, concludes Grunwald.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.